News headlines about AxoGen (NASDAQ:AXGN) have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AxoGen earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 45.8061545859271 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
AXGN has been the subject of several analyst reports. Lake Street Capital set a $38.00 target price on shares of AxoGen and gave the company a “buy” rating in a report on Friday, March 2nd. JMP Securities raised their price objective on shares of AxoGen from $27.00 to $34.00 and gave the stock a “market outperform” rating in a report on Thursday, March 1st. BidaskClub upgraded shares of AxoGen from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 23rd. William Blair initiated coverage on shares of AxoGen in a research report on Monday, February 5th. They set an “outperform” rating for the company. Finally, Cantor Fitzgerald set a $37.00 price objective on shares of AxoGen and gave the company a “buy” rating in a research report on Monday, January 8th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $31.71.
Shares of AxoGen (AXGN) traded up $0.55 during midday trading on Wednesday, hitting $35.70. 193,791 shares of the company traded hands, compared to its average volume of 308,082. The company has a current ratio of 4.07, a quick ratio of 3.53 and a debt-to-equity ratio of 0.79. AxoGen has a 12 month low of $9.70 and a 12 month high of $36.15. The stock has a market capitalization of $1,188.42, a P/E ratio of -119.00 and a beta of 0.10.
AxoGen (NASDAQ:AXGN) last released its quarterly earnings results on Wednesday, February 28th. The medical equipment provider reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.02. AxoGen had a negative net margin of 17.29% and a negative return on equity of 70.63%. The business had revenue of $16.97 million for the quarter, compared to analysts’ expectations of $16.38 million. During the same quarter in the previous year, the business posted ($0.10) earnings per share. The firm’s revenue for the quarter was up 48.7% compared to the same quarter last year. equities analysts predict that AxoGen will post -0.28 EPS for the current year.
In related news, CFO Jamie Mark Grooms sold 10,300 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $26.21, for a total value of $269,963.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 169,407 shares of company stock worth $4,593,013. 9.33% of the stock is currently owned by company insiders.
AxoGen Company Profile
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.